Halozyme Therapeutics Inc (HALO)
Return on assets (ROA)
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Net income | US$ in thousands | 281,594 | 202,129 | 402,710 | 129,085 | -72,240 |
| Total assets | US$ in thousands | 1,733,270 | 1,841,510 | 1,104,430 | 579,924 | 565,874 |
| ROA | 16.25% | 10.98% | 36.46% | 22.26% | -12.77% |
December 31, 2023 calculation
ROA = Net income ÷ Total assets
= $281,594K ÷ $1,733,270K
= 16.25%
Halozyme Therapeutics Inc.'s return on assets (ROA) has varied significantly over the past five years, indicating fluctuations in the company's ability to generate profits relative to its total assets. In 2023, the ROA stood at 16.25%, reflecting a strong performance compared to the previous year's 10.98%. The ROA in 2021 was exceptionally high at 36.46%, indicating efficient asset utilization.
However, in 2019, the company experienced a negative ROA of -12.77%, suggesting that the company's assets were not effectively used to generate profits. It is important for investors to understand the reasons behind such fluctuations in ROA to assess the company's operational efficiency and profitability.
Peer comparison
Dec 31, 2023